Company / R&D Expense
Q32 Bio Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$48.1M
FY2025
5-year range
$31.7M / $100.4M
FY2021-FY2025
Trend
+51.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $21M in FY2018 to $100M in FY2021.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of -11.6%.
Declined from $98M to $48M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -19.7%
- 5-Year CAGR
- -11.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.6%, indicating a declining trend.
- In FY2025, r&d expense increased 51.7% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.1M | +51.7% |
| FY2024 | $31.7M | -67.7% |
| FY2023 | $98.4M | +5.7% |
| FY2022 | $93.1M | -7.3% |
| FY2021 | $100.4M | +12.3% |
| FY2020 | $89.4M | +86.4% |
| FY2019 | $47.9M | +124.3% |
| FY2018 | $21.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026